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When managing the cataract of a 
patient with diabetes, you should 
remember that cataract surgery may 
make diabetic retinopathy worse. 
Eyes with mild to moderate 
non-proliferative diabetic retin-
opathy at the time of surgery are 
considered less at risk. Those with 
severe non-proliferative and prolifer-
ative diabetic retinopathy have a higher 
risk of progressive disease.1 Clinically 
significant macular oedema (CSMO) 
present at the time of surgery is likely to 
progress and eyes with previously treated 
CSMO are at increased risk of recurrence. 
The risk of progression is increased if the 
operation is complicated by excessive 
manipulation, vitreous loss, or severe 
post-operative inflammation.
Ideally, when the cataract does not 
preclude laser treatment, you should 
achieve and maintain 
effective control of retin-
opathy and maculopathy 
for at least three months 
before surgery. 
The severity of the 
cataract sometimes 
prevents adequate 
examination or treatment 
of the retina in patients 
with diagnosed or 
suspected severe 
non-proliferative and proliferative diabetic 
retinopathy. In this case, you should 
deliver pan-retinal photocoagulation 
either during the procedure or in the early 
post-operative period. When performing 
intraoperative pan-retinal photocoagu-
lation with an indirect ophthalmoscope, 
you should fill the anterior chamber with 
viscoelastic and place a corneal suture. 
Complete the pan-retinal photocoagu-
lation before inserting the intraocular 
lens. This will provide a stable anterior 
chamber and optimal view, particularly if 
you anticipate indentation of the periphery.
If you plan to give laser treatment with 
a contact lens in the early post-operative 
period, then you should suture the 
cataract wound. If it is still considered 
hazardous to use a contact lens then 
effective slit lamp laser can still be applied 
through a non-contact 78D or 90D lens. 
You can also use indirect laser for 
pan-retinal photocoagulation.
If the patient has diabetic maculopathy 
and/or more advanced retinopathy, 
consider intravitreal triamcinolone or 
anti-VEGF at the end of the procedure to 
reduce macular oedema. Triamcinolone 
targets the inflammation that exacer-
bates the oedema. Anti-VEGFs also 
reduce retinal swelling and may improve 
visual outcomes.2 Intravitreal steroids 
may cause raised intraocular pressure 
and anti-VEGF agents increase the risk of 
tractional complications in eyes with 
fibrovascular proliferation. You should still 
apply macular laser for CSMO post-opera-
tively.
In diabetes patients, it 
is very important to minimise 
post-operative inflam-
mation. You should use 
post-operative topical 
non-steroidal anti-inflam-
matory drugs in addition 
to routine topical steroid 
preparations, particularly 
in those with pre-existing 
macular oedema.3
In summary, diabetes patients with 
mild to moderate diabetic retinopathy and 
no maculopathy have a good prognosis 
following cataract surgery. You should 
treat more advanced retinopathy or 
maculopathy at least three months prior 
to surgery if possible. Whereas laser is the 
most recognised form of treatment, 
pharmacological agents play an important 
role in the management of these patients. 
It is also important to monitor high-risk 
patients in the post-operative period.
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centre of the exudate. It is not necessary 
to target individual microaneurysms. 
•	Diffuse macular oedema is treated by a 
grid laser in the area of thickening. 
Burns should be one burn width apart, 
using a spot size of 75 to 125 microns, 
duration 20–50 milliseconds. Do not 
use the repeat mode.
•	Start with a low power setting, around 
150 milliwatt, and increase the power 
until the desired endpoint is reached. 
Aim to produce a grey to cream change 
in colour. White means the laser is too 
hot and the power should be reduced. 
•	Take care not to encroach on the foveal 
avascular zone. It is wise to avoid 
treating perifoveal microaneurysms as 
this is likely to increase perifoveal 
capillary dropout (consider intravitreal 
bevacizumab instead). The chorioretinal 
atrophy caused by burns, especially 
intense burns, within 300 to 500 
microns of the fovea can years later 
extend into the fovea and cause vision 
loss, particularly in myopes. 
•	In patients with established foveal 
thickening or who are not responding to 
laser, consider intravitreal bevacizumab. 
In pseudophakic eyes, consider IVTA but 
watch the intraocular pressure closely.
Populations in low- and middle-income 
countries face a huge burden of blinding 
DR. Urgent advocacy is needed for govern-
ments to initiate programmes to address 
this. In the interim, every residency 
programme must provide training in the 
skills needed to manage DR, including 
interpreting investigations and delivering 
laser and other treatments. Refresher 
courses can be arranged for those not 
adequately trained or who have been 
without the necessary equipment for some 
time. We must also advocate for lasers 
and other necessary equipment wherever 
there is a trained ophthalmologist.
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‘You should 
remember that 
cataract surgery 
may make diabetic 
retinopathy worse’
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Consider intravitreal triamcinolone or anti-VEGF 
at the end of surgery to reduce macular oedema
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